Patent ID: 7803399

Claim:
An α v β 3 integrin receptor targeting liposome comprising a cationic lipid; a neutral lipid; a trivalent targeting lipid having a targeting domain and a hydrophobic domain bound to the targeting domain; and a nucleic acid complexed with the cationic lipid; the cationic lipid being present in an amount in the range of about 1 to about 50 mole percent, and said targeting lipid being present in an amount in the range of about 1 to about 20 mole percent, the mole percent values being based on total moles of lipid in the liposome, and the targeting domain including three non-peptidic α v β 3 integrin antagonists represented by formula (II): wherein in formula (II), R 4 and R 5 are each hydrogen, or together form a covalent bond; Y is —C(O)— or —CH 2 —; Z 2 is —C(O)—R 6 ; —C(O)OR 6 , or SO 2 R 6 ; R 6 is phenyl, substituted-phenyl, pyridyl, benzyl, substituted-benzyl; C 1 -C 4 haloalkyl, C 2 -C 30 alkyl, C 2 -C 30 alkenyl, C 2 -C 30 alkynyl, or cholesteryl; and Het is 2-pyridyl or 2-imidazolyl.